WuXi AppTec Investor Day 2026: The CRDMO 'Flywheel' Turns Eight Years of Certainty Into Compounding Returns
At its 2026 Investor Day on November 6, CFO Ms. Shi Ming laid out how the CRDMO model converts high growth into margins and cash flow. Full-year 2026 continuing-operations revenue guidance was raised to RMB 61.0–61.9B (+40% to +42% YoY), with backlog of RMB 76.7B — roughly 13x the 2018 level. Gross margin reached 54.2%, revenue per employee rose from RMB 540k to RMB 1.55M, and adjusted operating cash flow is about 16x that of 2018.
On November 6, WuXi AppTec (603259.SH / 2359.HK) held its 2026 Investor Day, where management walked several hundred online and on-site investors and analysts through industry trends and the company's capabilities. CFO Ms. Shi Ming used a 'flywheel' narrative to connect eight years of growth, profitability and cash generation: the CRDMO model keeps widening WuXi's lead by meeting clients' demand for certainty, then converts scale into profit and cash, and finally turns that into reinvestment and shareholder returns.
For 2026, the company guides continuing-operations revenue of RMB 61.0–61.9B, up 40%–42% YoY — about 8x the scale at its 2018 IPO. This is compounding across cycles, not a one-year spike: from 2018–2022 the industry's revenue CAGR was about 32% versus WuXi's 35%; since 2022, as the macro backdrop grew complex and R&D demand more diverse, the industry CAGR fell to about 11% while WuXi still delivered roughly 24%.
The source of growth is the integrated CRDMO pull-through. From 2018 to 3Q 2026, the share of active clients using both the R (research) and D&M (development and manufacturing) ends rose from 22% to 41%, contributing 96% of revenue in the first three quarters of this year. Front-end R continuously feeds high-quality molecules downstream, converting them into new development and manufacturing orders.
The order pool has therefore thickened: continuing-operations backlog climbed from about RMB 5.9B in 2018 to RMB 76.7B at 3Q 2026 — roughly 13x, a CAGR of about 40%. R-end backlog is about 2x the 2018 level, while D&M-end backlog reaches about 25x. A large, visible order pool lets the company plan capacity and allocate resources with a longer-term horizon.
The CRDMO model's other dividend is margin resilience. In 2018 WuXi's gross margin and the industry's were both around 39%; by the first three quarters of 2026 it had reached 54.2%, versus about 33.3% for the industry — the result of disciplined fine-tuning and scale-effect release.
Asset efficiency is a core driver. Revenue per employee rose from about RMB 540k in 2018 to an estimated RMB 1.55M in 2026 (about 3x), and the SG&A ratio fell from 15.3% to 6.9% in 3Q 2026. As front-end projects advance toward later-stage and commercial work, the structural jump in per-employee output is clear, while HI (human intelligence) plus AI lets the mature platform be reused directly by every new project without rebuilding from scratch.
Strong operating leverage translated scale solidly into profit and cash. Adjusted non-IFRS net margin rose from 18% in 2018 to 33% in 2025 and 40% in 3Q 2026; adjusted operating cash flow is estimated at about 16x the 2018 level and its share of revenue jumped from 16% to about 38%. Basic EPS reached RMB 6.7 in 3Q 2026, about 10x the full-year 2019 figure; cumulatively from 2019 to 1H 2026, dividends plus cancellation-style buybacks equalled about 42% of cumulative attributable net profit. Since its 2018 IPO, WuXi's total shareholder return is about 18x, versus about 4x for the China CXO index and about 2x for the global CXO and Nasdaq Biotech indices.
Reinvestment is what converts today's results into tomorrow's capacity. Capex was about RMB 25B in 2018–2022, supporting 24% growth through 2022–2026; 2023–2027E capex is expected to exceed RMB 30B, focused on expanding back-end D&M capacity. Solid-phase peptide synthesis reactors have been expanded to 130,000 L and oligonucleotide SPPS scale surpassed 8 mol; the Changzhou site passed an unannounced US FDA GMP inspection with zero findings. Globally, the new spray-drying suite at the Couvet site in Switzerland pairs with Taixing to form a China–Europe dual-location supply chain, while the Middletown, Delaware site and the Singapore site are expected to reach capacity-expansion and ramp-up milestones.